// App-Quantinova.ai

BSH2020‐EP‐116 : A retrospective single centre cohort study of the efficacy of weekly subcutaneous bortezomib containing treatment regimes in the management of plasma cell disorders

Researchers

Presenter

  • S. Bassiony

Principal Investigators

  • L. Peck

  • M. Dekmak

  • S. Alimam

  • M. Kazmi

  • K. Bailey

  • M. Gleeson

  • G. Milner

  • R. Bone

  • M. Streetly

Medical Centers

  • Hematology

  • Guy’s and St. Thomas’ NHS Foundation Trust

  • Haematology, Kings College Hospital, London,

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Nephrology

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Multiple Myeloma

  • Thrombocytopenia

  • Nephrotoxicity

  • Hypercalcaemia

  • Neutropenia

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Panobinostat

  • Prednisolone

  • daratumumab Intravenous

  • Thalidomide

  • Bortezomib

  • Melphalan

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved